Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;27(9):1420-1443.
doi: 10.2174/0929867326666190805151654.

Antiviral Activities of Human Host Defense Peptides

Affiliations
Review

Antiviral Activities of Human Host Defense Peptides

David C Brice et al. Curr Med Chem. 2020.

Abstract

Peptides with broad-spectrum antimicrobial activity are found widely expressed throughout nature. As they participate in a number of different aspects of innate immunity in mammals, they have been termed Host Defense Peptides (HDPs). Due to their common structural features, including an amphipathic structure and cationic charge, they have been widely shown to interact with and disrupt microbial membranes. Thus, it is not surprising that human HDPs have activity against enveloped viruses as well as bacteria and fungi. However, these peptides also exhibit activity against a wide range of non-enveloped viruses as well, acting at a number of different steps in viral infection. This review focuses on the activity of human host defense peptides, including alpha- and beta-defensins and the sole human cathelicidin, LL-37, against both enveloped and non-enveloped viruses. The broad spectrum of antiviral activity of these peptides, both in vitro and in vivo suggest that they play an important role in the innate antiviral defense against viral infections. Furthermore, the literature suggests that they may be developed into antiviral therapeutic agents.

Keywords: Antimicrobial peptide; LL-37; defensin; host defense peptide; innate immunity; virus..

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

References

    1. Chatterjee A; Modarai M; Naylor NR; Boyd SE; Atun R; Barlow J; Holmes AH; Johnson A; Robotham JV Quantifying drivers of antibiotic resistance in humans: a systematic review. Lancet Infect. Dis, 2018, 18(12), e368–e378. 10.1016/S1473-3099(18)30296-2 - DOI - PubMed
    1. Kumar P; Kizhakkedathu JN; Straus SK Antimicrobial peptides: diversity, mechanism of action and strategies to improve the activity and biocompatibility in vivo. Biomolecules, 2018, 8(1), 4. 10.3390/biom8010004 - DOI - PMC - PubMed
    1. de la Fuente-Núñez C; Silva ON; Lu TK; Franco OL Antimicrobial peptides: Role in human disease and potential as immunotherapies. Pharmacol. Ther, 2017, 178, 132–140. 10.1016/j.pharmthera.2017.04.002 - DOI - PubMed
    1. Hancock RE Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis, 2001, 1(3), 156–164. 10.1016/S1473-3099(01)00092-5 - DOI - PubMed
    1. Delattin N; Brucker K; Cremer K; Cammue BP; Thevissen K Antimicrobial peptides as a strategy to combat fungal biofilms. Curr. Top. Med. Chem, 2017, 17(5), 604–612. 10.2174/1568026616666160713142228 - DOI - PubMed